Fertility CEO resigns after embryo transferred to wrong patient in major bungle
Monash IVF CEO Michael Knaap resigned on June 12 just days after the fertility behemoth admitted to the transfer of the wrong embryo into a patient.
The board accepted Mr Knaap's resignation just two months after a similar incident occurred at a Brisbane clinic.
Monash IVF confirmed on June 10 that a patient was transferred her own embryo, rather than her partner's, at its Clayton clinic in Melbourne.
Monash IVF believes the June 5 bungle will "fall within the scope of its insurance coverage" as insurers were notified.
It comes two months after a Queensland woman gave birth to a stranger's child in an embryo mix-up at Monash IVF's Brisbane clinic.
Monash IVF said in a statement to the ASX that an internal investigation would be conducted.
The scope of an independent review into the Queensland mix-up, conducted by Fiona McLeod, would also be "extended", Monash IVF said.
Additional processes would be put in place at Monash IVF to avoid a similar mistake, the clinic said.
"Commencing immediately, Monash IVF will implement interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes," the clinic said.
"Whilst industry-leading electronic witness systems have and are being rolled out across Monash IVF, there remain instances and circumstances whereby manual witnessing is required.
"Monash IVF has disclosed the Incident to the relevant assisted reproductive technology (ART) regulators, namely the Reproductive Technology Accreditation Committee certifying body and Victorian Health Regulator.
The fertility clinic said it has "extended its sincere apologies to the affected couple".
University of Melbourne associate professor Alex Polyakov, a medical director of Genea Fertility Melbourne, said Australia's assisted reproduction sector was internationally recognised for its "rigorous oversight".
"The report of a second embryo transfer error is profoundly troubling and, while still extremely rare, shifts this issue from an isolated anomaly to one demanding broader reflection," he said.
"IVF clinics operate within some of the most highly regulated and scrutinised environments in medicine.
"Multiple safeguards, including dual verification and electronic tracking, exist at every step to prevent precisely this kind of error."
Monash IVF CEO Michael Knaap resigned on June 12 just days after the fertility behemoth admitted to the transfer of the wrong embryo into a patient.
The board accepted Mr Knaap's resignation just two months after a similar incident occurred at a Brisbane clinic.
Monash IVF confirmed on June 10 that a patient was transferred her own embryo, rather than her partner's, at its Clayton clinic in Melbourne.
Monash IVF believes the June 5 bungle will "fall within the scope of its insurance coverage" as insurers were notified.
It comes two months after a Queensland woman gave birth to a stranger's child in an embryo mix-up at Monash IVF's Brisbane clinic.
Monash IVF said in a statement to the ASX that an internal investigation would be conducted.
The scope of an independent review into the Queensland mix-up, conducted by Fiona McLeod, would also be "extended", Monash IVF said.
Additional processes would be put in place at Monash IVF to avoid a similar mistake, the clinic said.
"Commencing immediately, Monash IVF will implement interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes," the clinic said.
"Whilst industry-leading electronic witness systems have and are being rolled out across Monash IVF, there remain instances and circumstances whereby manual witnessing is required.
"Monash IVF has disclosed the Incident to the relevant assisted reproductive technology (ART) regulators, namely the Reproductive Technology Accreditation Committee certifying body and Victorian Health Regulator.
The fertility clinic said it has "extended its sincere apologies to the affected couple".
University of Melbourne associate professor Alex Polyakov, a medical director of Genea Fertility Melbourne, said Australia's assisted reproduction sector was internationally recognised for its "rigorous oversight".
"The report of a second embryo transfer error is profoundly troubling and, while still extremely rare, shifts this issue from an isolated anomaly to one demanding broader reflection," he said.
"IVF clinics operate within some of the most highly regulated and scrutinised environments in medicine.
"Multiple safeguards, including dual verification and electronic tracking, exist at every step to prevent precisely this kind of error."
Monash IVF CEO Michael Knaap resigned on June 12 just days after the fertility behemoth admitted to the transfer of the wrong embryo into a patient.
The board accepted Mr Knaap's resignation just two months after a similar incident occurred at a Brisbane clinic.
Monash IVF confirmed on June 10 that a patient was transferred her own embryo, rather than her partner's, at its Clayton clinic in Melbourne.
Monash IVF believes the June 5 bungle will "fall within the scope of its insurance coverage" as insurers were notified.
It comes two months after a Queensland woman gave birth to a stranger's child in an embryo mix-up at Monash IVF's Brisbane clinic.
Monash IVF said in a statement to the ASX that an internal investigation would be conducted.
The scope of an independent review into the Queensland mix-up, conducted by Fiona McLeod, would also be "extended", Monash IVF said.
Additional processes would be put in place at Monash IVF to avoid a similar mistake, the clinic said.
"Commencing immediately, Monash IVF will implement interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes," the clinic said.
"Whilst industry-leading electronic witness systems have and are being rolled out across Monash IVF, there remain instances and circumstances whereby manual witnessing is required.
"Monash IVF has disclosed the Incident to the relevant assisted reproductive technology (ART) regulators, namely the Reproductive Technology Accreditation Committee certifying body and Victorian Health Regulator.
The fertility clinic said it has "extended its sincere apologies to the affected couple".
University of Melbourne associate professor Alex Polyakov, a medical director of Genea Fertility Melbourne, said Australia's assisted reproduction sector was internationally recognised for its "rigorous oversight".
"The report of a second embryo transfer error is profoundly troubling and, while still extremely rare, shifts this issue from an isolated anomaly to one demanding broader reflection," he said.
"IVF clinics operate within some of the most highly regulated and scrutinised environments in medicine.
"Multiple safeguards, including dual verification and electronic tracking, exist at every step to prevent precisely this kind of error."
Monash IVF CEO Michael Knaap resigned on June 12 just days after the fertility behemoth admitted to the transfer of the wrong embryo into a patient.
The board accepted Mr Knaap's resignation just two months after a similar incident occurred at a Brisbane clinic.
Monash IVF confirmed on June 10 that a patient was transferred her own embryo, rather than her partner's, at its Clayton clinic in Melbourne.
Monash IVF believes the June 5 bungle will "fall within the scope of its insurance coverage" as insurers were notified.
It comes two months after a Queensland woman gave birth to a stranger's child in an embryo mix-up at Monash IVF's Brisbane clinic.
Monash IVF said in a statement to the ASX that an internal investigation would be conducted.
The scope of an independent review into the Queensland mix-up, conducted by Fiona McLeod, would also be "extended", Monash IVF said.
Additional processes would be put in place at Monash IVF to avoid a similar mistake, the clinic said.
"Commencing immediately, Monash IVF will implement interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes," the clinic said.
"Whilst industry-leading electronic witness systems have and are being rolled out across Monash IVF, there remain instances and circumstances whereby manual witnessing is required.
"Monash IVF has disclosed the Incident to the relevant assisted reproductive technology (ART) regulators, namely the Reproductive Technology Accreditation Committee certifying body and Victorian Health Regulator.
The fertility clinic said it has "extended its sincere apologies to the affected couple".
University of Melbourne associate professor Alex Polyakov, a medical director of Genea Fertility Melbourne, said Australia's assisted reproduction sector was internationally recognised for its "rigorous oversight".
"The report of a second embryo transfer error is profoundly troubling and, while still extremely rare, shifts this issue from an isolated anomaly to one demanding broader reflection," he said.
"IVF clinics operate within some of the most highly regulated and scrutinised environments in medicine.
"Multiple safeguards, including dual verification and electronic tracking, exist at every step to prevent precisely this kind of error."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Age
2 days ago
- The Age
Our fertility industry is a mess. As a donor, I know what could fix it
It pains me to say Australia's fertility industry is a mess because it's a system into which I've donated sperm to create humans, in good faith. You'd hope, after the notorious malpractice of past practitioners, the industry – which insists it's reformed from those bad old days – would enforce the strictest of procedures and the most watertight regulation. Sadly not. The profit-driven industry regulates itself, which is proving problematic, to say the least. Staff report being burnt out enough to make mistakes, and the mistakes have emerged with alarming pace in recent weeks. Monash IVF has twice transferred the wrong embryo into a woman. The first time, reported in April, experts said that, while it was worrying, it was an extremely rare, isolated case of human error. Then it happened again last month. My own investigation this week revealed two leading Australian fertility clinics – both owned by Virtus Health – are sending sperm donors inaccurate lists of the children born from their donation. Donors are being introduced to children who are potentially not even biologically theirs. Melbourne IVF sent one donor the wrong child list three times. He's now distressed the kids he has formed relationships with aren't related to him. While voices calling for calm seek to reassure us that Australia remains a very safe place to receive fertility treatment, try telling that to the anguished and conflicted donors who spoke to me. Or to the two women who gave birth to children who aren't theirs. Loading These problems are the tip of the iceberg too. The fertility industry is a bureaucratic quagmire, and it feels like it is now in crisis. It is governed by more than 40 pieces of differing state legislation in nine jurisdictions. It should be governed by a statutory, nationally applicable set of regulations. Urgent changes are clearly needed, which is why a rapid review of the industry was announced by federal Health Minister Mark Butler. He has his work cut out. The most important stakeholders he must listen to are donor-conceived people themselves – the humans created from this industry. They have a set of requests he should prioritise above all others. But as a donor, if we could add one urgent thing to his to-review list, it would be this. Clinics should build in and pay for DNA testing of donors and the children born from their donations as part of their later matching procedures.
Sydney Morning Herald
2 days ago
- Sydney Morning Herald
Our fertility industry is a mess. As a donor, I know what could fix it
It pains me to say Australia's fertility industry is a mess because it's a system into which I've donated sperm to create humans, in good faith. You'd hope, after the notorious malpractice of past practitioners, the industry – which insists it's reformed from those bad old days – would enforce the strictest of procedures and the most watertight regulation. Sadly not. The profit-driven industry regulates itself, which is proving problematic, to say the least. Staff report being burnt out enough to make mistakes, and the mistakes have emerged with alarming pace in recent weeks. Monash IVF has twice transferred the wrong embryo into a woman. The first time, reported in April, experts said that, while it was worrying, it was an extremely rare, isolated case of human error. Then it happened again last month. My own investigation this week revealed two leading Australian fertility clinics – both owned by Virtus Health – are sending sperm donors inaccurate lists of the children born from their donation. Donors are being introduced to children who are potentially not even biologically theirs. Melbourne IVF sent one donor the wrong child list three times. He's now distressed the kids he has formed relationships with aren't related to him. While voices calling for calm seek to reassure us that Australia remains a very safe place to receive fertility treatment, try telling that to the anguished and conflicted donors who spoke to me. Or to the two women who gave birth to children who aren't theirs. Loading These problems are the tip of the iceberg too. The fertility industry is a bureaucratic quagmire, and it feels like it is now in crisis. It is governed by more than 40 pieces of differing state legislation in nine jurisdictions. It should be governed by a statutory, nationally applicable set of regulations. Urgent changes are clearly needed, which is why a rapid review of the industry was announced by federal Health Minister Mark Butler. He has his work cut out. The most important stakeholders he must listen to are donor-conceived people themselves – the humans created from this industry. They have a set of requests he should prioritise above all others. But as a donor, if we could add one urgent thing to his to-review list, it would be this. Clinics should build in and pay for DNA testing of donors and the children born from their donations as part of their later matching procedures.
West Australian
2 days ago
- West Australian
ASX Runners of the Week: Amplia, archTIS and Vanadium Resources
If you were looking for correlation between the seemingly continuous breakouts of military hostilities between nuclear-armed nations and the market - good luck. The ASX continued at near all-time highs this week, pulling back a fraction by Friday, as conflict between Iran and Israel continued to rise. The oil price surged a further 10 per cent this week as Israel turned its focus from Iran's nuclear facilities to targeting its oil and gas infrastructure. Uranium stocks were the week's main winners. Surprisingly, they were not fuelled directly by global drivers, but rather by investment heavyweight Sprott's physical uranium trust purchase of $200 million worth of uranium oxide, which was announced on Monday. The result for uranium stocks on the index was deafening. Uranium miners Boss Energy, Paladin Energy and Deep Yellow were among the most heavily shorted on the ASX, making up three of the top 10 shorted companies. A sharp increase in uranium caused a two-fold effect of en masse buying and short seller panic to close out positions, with the big three uranium stocks all surging up 20 per cent on the day. In a rare shake-up, no Australian-based resource companies feature on this week's Bulls N' Bears' ASX Runners list. Instead, the chocolates went to a groundbreaking Aussie biotech story, which could be on to the makings of one of the biggest breakthroughs in oncology treatment in years. AMPLIA THERAPEUTICS (ASX: ATX) Up 339% (5.7c – 25c) This week's Bulls N' Bears ASX Runner of the Week is biotech trailblazer Amplia Therapeutics, which sent the market into an absolute tailspin thanks to a jaw-dropping set of results from a clinical trial for incredibly nasty pancreatic cancer. On Monday, the company announced a pathological complete response – no detectable signs of cancer - in a patient enrolled in its ACCENT trial of a drug therapy to limit tumour growth. The trial combined the therapy narmafotinib with two other drugs to treat a patient with metastatic (stage IV) pancreatic cancer. After surgery, the patient's primary and metastatic tumours showed no live cancer cells, a unicorn-rare outcome in this brutal disease, where no detectable cancer signs are less common than a sunny day in Melbourne. The market mumbled and murmured through Wednesday, then stacked 42 per cent onto Amplia's share price. Thursday brought a different tune: a second patient, out of 55 enrolled in the trial, achieved a confirmed complete response, with all tumour lesions vanishing for more than two months. In advanced pancreatic cancer, where one complete response in 431 patients is headline-worthy, two in a trial appears groundbreaking. The market lost its collective marbles and the company's shares rocketed to 25 cents per share – up 339 per cent - on Friday with more than $30 million in shares traded on the week. The move also delivered a handy little profit for Amplia's second largest shareholder Acorn Capital, which picked up a further $350,000 worth of shares on Monday, when it saw value before the broader market. Pancreatic cancer is Australia's eighth most common cancer and has a dismal 12.5 per cent five-year survival rate. With United States Food and Drug Administration registration already in the bag, Amplia's drug looks to be on the charge to transform oncology, especially as healthcare systems globally grapple with rising cancer burdens and demand for precision therapies. ARCHTIS LTD (ASX: AR9) Up 287% (6.2c – 24c) Taking out silver on this week's Runners list is cybersecurity expert archTIS Limited, which saw its share price catapult 390 per cent by Wednesday, before the ASX killjoys slammed it into suspension, ending any hopes the company could take out the coveted Bulls N' Bears podium. The company released a duo of blockbuster defence contracts on Monday and Wednesday, before archTIS' management rubbed shoulders with some of the world's cybersecurity elite. On Monday, the company unveiled a US Defence Department contract for 1000 licences for its NC Protect data security software, worth $38,500 a pop for six months, to lock down sensitive data in Microsoft's DoD365 cloud. After months of brutal testing by the prime global contractor, NC Protect came up trumps as the only integrated solution for robust, scalable attribute-based access control. ArchTIS says its product could address a potential 150,000-user rollout across the warfighter network, if it proves a success for the defence department. Amazingly, $100,000 worth of shares traded on Monday, before going supersonic on Tuesday, to push the company's share price up 100 per cent from last week's close on $600,000 shares traded. ArchTIS dropped a second bomb on Wednesday, announcing a three-year $263,185 deal for 400 users with a United Kingdom-based aerospace and defence titan, which is poised to be a blueprint for more than 100,000 potential users in a global Microsoft 365 rollout. The company's share price hit a peak of 24c for a gain of 287 per cent this week, on $1.4 million in intraday trading, before the compliance overlords at the ASX cried 'disorderly market' and placed the company into suspension, where it remains. It's likely a few day traders were caught flat-footed by the suspension and were no doubt scouring around to come up with the cash to settle on trades they had hoped to flip by market close on Wednesday. In a world where cyberattacks are spiking, archTIS' NC Protect could fulfil a crucial defence need. Its ability to secure sensitive communications in cloud environments, such as the DoD365 and Microsoft 365 platforms, is critical as nations race to shield their military and industrial data from state-sponsored threats. With geopolitical tensions boiling and the US and UK doubling down on cybersecurity to protect their defence industrial bases, archTIS' tech is perfectly timed to cash in on the global push for ironclad digital fortresses, making it a potential darling in the market and of Western military alliances. VANADIUM RESOURCES LTD (ASX: VR8) Up 185% (1.3c – 3.7c) Snagging the final spot on the Runners of the Week podium is the aptly named critical minerals developer Vanadium Resources, which shot out of a cannon on Tuesday, after inking a non-binding memorandum of understanding (MoU) with China Precious Asia (CPA). Vanadium will supply 1.2 million tonnes per annum of vanadium-rich magnetite direct shipping ore to the heavyweight global metals trader from its world-class Steelpoortdrift vanadium project in South Africa. The MoU positions Vanadium to tap into early cash flows at the fully permitted Steelpoortdrift, a behemoth resource with 680 million tonnes of ore at 0.70 per cent vanadium oxide, which is equivalent to 4.74Mt contained vanadium. That rate is enough to keep the company's lights on for more than 180 years. CPA will handle loading and collection of the direct shipping ore, with Vanadium retaining a nimble ±25 per cent supply flexibility each month, kicking off by December this year. Management believes the material positive operating cash flows will fast track its development, with good reason. Steelpoortdrift's vanadium-rich ore also brims with iron-rich magnetite, making it a dual-treat commodity in the Asian steel market. The news sent the company's long-beleaguered share price soaring a cheeky 185 per cent from last Friday's 1.3c close to a 3.7c peak on $230,000 in stock traded. Vanadium is also actively sniffing out profit-share deals and acquisitions to bolster its near-term game plan without derailing the direct shipping ore opportunity. The deal looks beneficial for both parties as vanadium supplies are projected to be in global deficit this year, coupled with China's ambitions to diversify from its dependence on Australian-based iron ore. Steelpoortdrift's high-grade, low-cost direct shipping option has reignited global and now market interest in the company. If Vanadium can lock in a binding agreement with CPA, this plucky minnow could vault into the vanadium big league and potentially self-fund its own mine development. Is your ASX-listed company doing something interesting? Contact:
